Coronary Steal Via Natural Internal Mammary Artery-To-Coronary Artery Bypasses
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jan 5, 2015
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
CORONARY ARTERY DISEASE AND THE BENEFIT OF BYPASSES
Despite considerable advances in medicine, cardiovascular diseases remain the number one cause of death globally. In industrialized countries, coronary artery disease (CAD) is the leading cause of death, consequence of myocardial infarction (MI).
In patients with acute coronary syndrome, percutaneous coronary intervention (PCI) has been shown to improve outcomes.2 However, in stable CAD, PCI has not been demonstrated to reduce the incidence of myocardial infarction or death. Coronary artery bypass grafting (CABG) was superior to PCI in p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Referred for elective coronary angiography
- • Written informed consent to participate in the study
- Exclusion Criteria:
- • Acute coronary syndrome; unstable cardiopulmonary conditions
- • Severe cardiac valve disease
- • Congestive heart failure NYHA III-IV
- • Prior coronary artery bypass surgery / prior cardiac surgery
- • Coronary artery disease unsuitable for intracoronary pressure measurements
- • Prior Q-wave myocardial infarction in the vascular territory undergoing collateral function determination
- • Severe renal or hepatic failure
- • Pregnancy
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Christian Seiler, MD, Prof.
Principal Investigator
Department of Cardiology, Bern University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials